Folic acid inhibits COLO-205 colon cancer cell proliferation through activating the FRα/c-SRC/ERK1/2/NFκB/TP53 pathway: In vitro and in vivo studies

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kuo, Chun Ting ^a   Chang, Chieh ^b   Lee, Wen Sen ^a,c,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE P60; PROTEIN P53; TP53 PROTEIN, HUMAN;

CELL PROLIFERATION; DRUG EFFECTS; HUMAN; IN VITRO STUDY; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; FOLIC ACID; HUMANS; IN VITRO TECHNIQUES; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; PROTO-ONCOGENE PROTEINS PP60(C-SRC); TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84930959009     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11187     Document Type: Article

References (36)

1. Mehta, R. et al. Role of folic acid and energy intake in nucleic acid synthesis. J. Biol. Chem. 234, 625-627 (1959).
2. Weinstein, S. J. et al. Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine". Cancer Epidemiol. Biomarkers Prev. 12, 1271-1272 (2003).
3. Camilo, E. et al. Folate synthesized by bacteria in the human upper small intestine is assimilated by the host. Gastroenterology 110, 991-998 (1996).
4. Mason, J. B. & Choi, S. W. Folate and carcinogenesis: developing a unifying hypothesis. Adv. Enzyme Regul. 40, 127-141 (2000).
5. Verhaar, M. C., Stroes, E. & Rabelink, T. J. Folates and cardiovascular disease. Arterioscl. Throm. Vas. Biol. 22, 6-13 (2002).
6. Laurence, K. M., James, M., Miller, M. H., Tennant, G. B. & Campbell, H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. BMJ 282, 1509-1511 (1981).
7. Vergel, R. G., Sanchez, L. R., Heredero, B. L., Rodriguez, P. L. & Martinez, A. J. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat. Diagn. 10, 149-152 (1990).
8. Vollset, S. E. et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomized trials: meta-analyses of data on 50,000 individuals. Lancet 23, 1029-1036 (2013).
9. Clarke, R. et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37,485 individuals. Arch. Intern. Med. 170, 1622-1631 (2010).
10. Sanjoaquin, M. A., Allen, N., Couto, E., Roddam, A. W. & Key, T. J. Folate intake and colorectal cancer risk: a meta-analytical approach. Int. J. Cancer 113, 825-828 (2005).
11. Kim, Y. I. Does a high folate intake increase the risk of breast cancer? Nutr. Rev. 64, 468-475 (2006).
12. Choi, S. W. & Mason, J. B. Folate status: effects on pathways of colorectal carcinogenesis. J. Nutr. 132, 2413S-2418S (2002).
13. Kim, Y. I. Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer? Cancer Epidemiol. Biomarkers Prev. 13, 511-519 (2004).
14. Kim, Y. I. Folate and carcinogenesis: evidence, mechanisms and implications. J. Nutr. Biochem. 10, 66-88 (1999).
15. Kim, Y. I. Folate and colorectal cancer: an evidence-based critical review. Mol. Nutr. Food Res. 51, 267-292 (2007).
16. Clapin, H. F., Fritschi, L., Iacopetta, B. & Heyworth, J. S. Dietary and supplemental folate and the risk of left- and right-sided colorectal cancer. Nutr. Cancer 64, 937-945 (2012).
17. Lin, S. Y. et al. Folic acid inhibits endothelial cell proliferation though activating the c-SRC/ERK 2/NF-kB/p53 pathway mediated by folic acid receptor. Angiogenesis 15, 671-83 (2012).
18. Wong, K. B. et al. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. USA 96, 8438-8442 (1999).
19. Hsu, S. P. & Lee, W. S. Progesterone receptor activation of extranuclear signaling pathways in regulating p53 expression in vascular endothelial cells. Mol. Endocrinol. 25, 421-432 (2011).
20. Shao, R. G. et al. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function Cancer Res. 57, 4029-4035 (1997).
21. Drewinko, B., Romsdahl, M. M., Yang, L. Y., Ahearn, M. J. & Trujillo, J. M. Establishment of a human carcinoembryonic antigenproducing colon adenocarcinoma cell line. Cancer Res. 36, 467-475 (1976).
22. Hsu, S. P., Ho, P. Y., Juan, S. H., Liang, Y. C. & Lee, W. S. Progesterone inhibits human endothelial cell proliferation though a p53-dependent pathway. Cell. Mol. Life Sci. 65, 3839-3850 (2008).
23. Honda, R. & Yasuda, H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO. J. 18, 22-27 (1999).
24. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. & Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945-8951 (2000).
25. Shirane, M. et al. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J. Biol. Chem. 274, 13886-13893 (1999).
26. Weitman, S. D. et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52, 3396-401 (1992).
27. Shen, F., Ross, J. F., Wang, X. & Ratnam, M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 33, 1209-1215 (1994).
28. Wu, M., Gunning, W. & Ratnam, M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. 8, 775-782 (1999).
29. Ross, J. F. et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 85, 348-357 (1999).
30. Shen, F., Wu, M., Ross, J. F., Miller, D. & Ratnam, M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry 34, 5660-5665 (1995).
31. Spiegelstein, O., Eudy, J. D. & Finnell, R. H. Identification of two putative novel folate receptor genes in humans and mouse. Gene 258, 117-125 (2000).
32. Barber, R. C., Lammer, E. J., Shaw, G. M., Greer, K. A. & Finnell, R. H. The role of folate transport and metabolism in neural tube defect risk. Mol. Genet. Metab. 66, 1-9 (1999).
33. Lin, S. Y. et al. Magnolol Suppresses Proliferation of Cultured Human Colon and Liver Cancer Cells by Inhibiting DNA Synthesis and Activating Apoptosis. J. Cell. Biochem. 84, 532-544 (2002).
34. Bartussek, C., Naumann, U. & Weller, M. Accumulation of mutant p53 (V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. Exp. Cell Res. 253, 432-439 (1999).
35. Jhaveri, M. S., Rait, A. S., Chung, K. N., Trepel, J. B. & Chang, E. H. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol. Cancer Ther. 3, 1505-1512 (2004).
36. Lin, S. Y. et al. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J. Cell. Biochem. 84, 532-544 (2002).